drugset
drugset / Trial / NCT00861939

To Demonstrate the Relative Bioavailability of Bupropion HCI 300 mg Extended-Release Tablets Under Fasting Conditions

NCT00861939 ↗

Phase 1 Completed 28 enrolled Sandoz
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to demonstrate the relative bioequivalence of Bupropion HCI 300 mg ER Tablets under fasting conditions.

Timeline

Start
2004-03
Primary completion
2004-04
Completion
2004-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 300 mg —

Indications

depressive disorder